MedPath

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

Phase 2
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: Placebo
Registration Number
NCT01647516
Lead Sponsor
Celgene
Brief Summary

The purpose of this study is to determine whether RPC1063 is effective in the treatment of ulcerative colitis (UC).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
199
Inclusion Criteria
  • Ulcerative colitis (UC) confirmed on endoscopy
  • Moderately to severely active UC (Mayo score 6-12)
Exclusion Criteria
  • Current use of anti-TNF agents

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ozanimod 0.5 mgOzanimodParticipants received 0.5 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 0.5 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
PlaceboPlaceboIdentically matching placebo capsules daily for 32 weeks followed by an optional open label treatment period.
Ozanimod 1 mgOzanimodParticipants received 1 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 1 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants Who Achieved Clinical Remission Based on the Central Read of the Mayo Score (MS), at Week 8Week 8

Clinical Remission was defined as: Mayo score of \<2 points and with no individual subscore of \> 1 point.

The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment) with each item graded semi-quantitatively on a scale of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, with a result ranging from 0 to 12 points. Higher scores represent more severe disease.

* Stool Frequency Subscore (SFS)

* Rectal bleeding Subscore (RBS)

* Endoscopy Subscore

* Physician's Global Assessment (PGA)

Clinical Remission was based on the 4-component Mayo definition.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants Who Achieved a Clinical Response in the Mayo Score (MS) at Week 8Week 8

Clinical response was defined as a reduction from baseline in Mayo score ≥3 points and ≥30%, and a decrease from baseline in the rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of ≤ 1 point.

The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment) with each item graded semi-quantitatively on a scale of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, with a result ranging from 0 to 12 points. Higher scores represent more severe disease.

Clinical Respone was based on the 4-component Mayo definition.

Change From Baseline in Mayo Score at Week 8Baseline to Week 8

The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment) with each item graded semi-quantitatively on a scale of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, with a result ranging from 0 to 12 points. Higher scores represent more severe disease.

* Stool Frequency Subscore (SFS)

* Rectal bleeding Subscore (RBS)

* Endoscopy Subscore

* Physician's Global Assessment (PGA)

Percentage of Participants With Mucosal Healing at Week 8Week 8

Mucosal healing is defined as an endoscopy subscore ≤ 1 point. Endoscopy subscores were calculated based on central endoscopy reading.

The endoscopy scale:

0 = Normal or inactive disease

1. = Mild disease (erythema, decreased vascular pattern, mild friability)

2. = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions)

3. = Severe disease (spontaneous bleeding, ulceration)

Percentage of Participants Who Achieved Clinical Remission in the Mayo Score at Week 32Week 32

Clinical Remission was defined as: Mayo score of \<2 points and with no individual subscore of \> 1 point.

The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment) with each item graded semi-quantitatively on a score of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, with a result ranging from 0 to 12 points. Higher scores represent more severe disease.

* Stool Frequency Subscore (SFS)

* Rectal bleeding Subscore (RBS)

* Endoscopy Subscore

* Physician's Global Assessment (PGA)

Percentage of Participants Who Achieved Clinical Response at Week 32Week 32

Clinical response was defined as a reduction from baseline in Mayo score ≥3 points and ≥30%, and a decrease from baseline in the rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of ≤ 1 point.

The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment) with each item graded semi-quantitatively on a scale of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, with a result ranging from 0 to 12 points. Higher scores represent more severe disease.

* Stool Frequency Subscore (SFS)

* Rectal bleeding Subscore (RBS)

* Endoscopy Subscore

* Physician's Global Assessment (PGA)

Percentage of Participants With Mucosal Healing at Week 32Week 32

Mucosal healing is defined as an endoscopy subscore ≤ 1 point. Endoscopy subscores were calculated based on central endoscopy reading.

The endoscopy scale:

0 = Normal or inactive disease

1. = Mild disease (erythema, decreased vascular pattern, mild friability)

2. = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions)

3. = Severe disease (spontaneous bleeding, ulceration)

Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Induction PeriodFrom the first dose of investigational product (IP) up to 90 days after the last dose of IP or at follow-up visit; the mean total duration of IP exposure was 52.8 days, 56.1 days and 50.8 days respectively for 0.5 mg, 1 mg ozanimod and placebo

A TEAE was defined as any event with an onset date on or after first dose date or any ongoing event on the first dose date that worsens in severity after first dose date and until 90 days following the last dose of treatment with the study drug. earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = an AE usually transient in nature and generally not interfering with normal activities; Moderate = an AE that is sufficiently discomforting to interfere with normal activities; Severe = an AE that is incapacitating and prevents normal activities.

Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Maintenance PeriodFrom the first dose of IP up to 90 days after the last dose of IP or at follow-up visit; the mean total duration of IP exposure was 156.3 days, 171.1 days and 154.5 days respectively for 0.5 mg, 1 mg ozanimod and placebo.

A TEAE was defined as any event with an onset date on or after first dose date or any ongoing event on the first dose date that worsens in severity after first dose date and until 90 days following the last dose of treatment with the study drug. earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = an AE usually transient in nature and generally not interfering with normal activities; Moderate = an AE that is sufficiently discomforting to interfere with normal activities; Severe = an AE that is incapacitating and prevents normal activities.

Number of Participants With TEAE During the Open-Label Treatment Period (OLP)From the first dose of IP until 90 days after the last dose of IP or at follow-up visit; the mean total duration of study drug exposure in the OLP was 2.42 years

A TEAE was defined as any event with an onset date on or after first dose date or any ongoing event on the first dose date that worsens in severity after first dose date and until 90 days following the last dose of treatment with the study drug. earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = an AE usually transient in nature and generally not interfering with normal activities; Moderate = an AE that is sufficiently discomforting to interfere with normal activities; Severe = an AE that is incapacitating and prevents normal activities.

Trial Locations

Locations (88)

Anaheim Clinical Trials

🇺🇸

Anaheim, California, United States

University of California San Diego

🇺🇸

La Jolla, California, United States

Alliance Clinical Research

🇺🇸

Oceanside, California, United States

Atlanta Gastroenterology Associates, LLC

🇺🇸

Atlanta, Georgia, United States

Chevy Chase Clinical Research

🇺🇸

Chevy Chase, Maryland, United States

Endoscopic Microsurgery Associates

🇺🇸

Towson, Maryland, United States

Clinical Research Institute of Michigan, LLC

🇺🇸

Chesterfield, Michigan, United States

Long Island Clinical Research Associates

🇺🇸

Great Neck, New York, United States

University of North Carolina

🇺🇸

Chapel Hill, North Carolina, United States

Consultants for Clinical Research

🇺🇸

Cincinnati, Ohio, United States

Scroll for more (78 remaining)
Anaheim Clinical Trials
🇺🇸Anaheim, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.